No Data
No Data
BofA Securities Adjusts Price Target on Day One Biopharmaceuticals to $25 From $28, Maintains Buy Rating
BofA Securities Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Cuts Target Price to $25
Day One Biopharm Is Maintained at Buy by Jones Trading
Day One Biopharmaceutical Analyst Ratings
Day One Biopharmaceuticals (DAWN) Posts Stellar Q3 but With Extreme Concentration Risk
JonesTrading Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Cuts Target Price to $34